ENDRA Life Sciences Inc. — Director's Dealing 2018

Nov 15, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2018-11-13

Reporting Person: Thornton Michael Milos (Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-13	Common Stock	C	29762	$1.68	Acquired	89750	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-13	Convertible Promissory Note	$1.68	C		Disposed	2018-12-31	Common Stock (29762)	Direct

Footnotes

F1: These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2).

F2: Pursuant to the terms of the Convertible Promissory Note (the "Note"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%.